Jakub Porzycki / NurPhoto via Getty Images Key Takeaways The S&P 500 slipped 0.8% on Tuesday, May 6, 2025, falling for a second straight day as investors awaited news on U.S. tariff policies and prepare dfor tomorrow’s Federal Reserve announcement. Moderna and Vertex Pharmaceuticals shares plunged after pausing a cystic fibrosis clinic trial, while drugmakers also declined on the FDA’s appointment of a new top vaccine regulator. Constellation Energy jumped on a strong earnings report elevated by continued strong power demand for AI facilities. The S&P 500 dropped for a second straight session as investors digested corporate earnings reports, waited for tariff updates and readied themselves for tomorrow’s Federal Reserve’s announcement on interest rates. The S&P 500 fell 0.8% on Tuesday, while the Dow Jones Industrial Average slipped by about 1% and the Nasdaq was lower by 0.9%. The results marked a second straight day of declines for stocks after a run of nine consecutive winning sessions for the S&P 500 and Dow. Read today's full markets coverage here. Palantir’s (PLTR) stock dropped by 12%. The AI software firm didn’t deliver strong enough earnings to impress investors after it reported adjusted earnings per share that were in line with analysts' expectations. The company reported a batter-than-expected 39% jump in quarterly revenue and raised its full-year outlook on growing demand for its AI software. Analysts raised questions about its valuation, as the stock price was up over 40% for 2025 and 400% over the past 12 months. Vertex Pharmaceuticals (VRTX) was down 10% after it paused a cystic fibrosis clinic trial it was conducting with Moderna (MRNA). The delayed trial at Vertex was part of a series of costs that led to worse-than-expected quarterly earnings. Pharmaceutical stocks were also weighed down by news that the Food and Drug Administration named Dr. Vinay Prasad, a critic of the U.S. Covid-19 response, as its top vaccine regulator. Regeneron Pharmaceutical (REGN) was down more than 7%, while Eli Lilly (LLY) sank almost 6% and Bristol-Myers Squibb (BMY) was down 5%. Moderna was down around 12%. DoorDash (DASH) stock dropped by more than 7% after it moved up its scheduled earnings result release to this morning, with the food delivery service reporting underwhelming revenue for the quarter. The company said it was buying U.K. firm Deliveroo for nearly $4 billion and restaurant booking platform SevenRooms for $1.2 billion. Constellation Energy (CEG) shares rose 10% to deliver the best performance in the S&P 500 after the nuclear energy provider continued to benefit from artificial intelligence-driven electricity demand. It beat its quarterly operating revenue forecasts and maintained its 2025 outlook, even though its profits were weaker than expected. The company also said its $26.6 billion purchase of natural gas and geothermal energy firm Calpine is on track to be completed by the end of the year. Story Continues Engineering firm Leidos Holdings (LDOS) was 4.6% higher after its better-than-expected results indicated that the company may not see too much earnings loss from cuts to government spending from programs like the Department of Government Efficiency. Ford Motor (F) shares climbed by 2.7% after it reported quarterly earnings that beat analysts’ expectations but suspended its full-year outlook amid uncertainty about tariffs. Super Micro Computer (SMCI) was up by 2.4% ahead of its earnings report, due after markets closed. Read the original article on Investopedia View Comments
S&P 500 Gains & Losses Today: Stocks Fall for Second Day as Palantir, Pharmaceuticals Drop
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...